Clinical trial NCT02231957: Text Message Vaccine Reminders for Adolescents With Chronic Medical Conditions
Official title: Text Message Vaccine Reminders for Adolescents With Chronic Medical Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Vaccination
Lead sponsor: Columbia University
Sponsor class: OTHER
Collaborators: name: Pfizer
First posted: 2014-09-04
Enrollment: 416
Sex: ALL
Minimum age (years): 11
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: There are a growing number of adolescents with chronic medical conditions in the United States. The Advisory Committee on Immunization Practices (ACIP) recommends HPV vaccination and annual influenza vaccination of all adolescents. Pneumococcal polysaccharide vaccination is also recommended for certain high-risk patients. Limited studies suggest that vaccination coverage of this population remains sub-optimal. Text message vaccine reminder/recall has been shown to be effective in increasing uptake of select pediatric and adolescents vaccines, but has yet to be examined among patients with chronic medical conditions who may also face unique barriers to vaccination. This intervention aims to implement and evaluate the use of text message vaccine reminders among urban low-income minority adolescents with chronic medical conditions. This investigator-initiated study is supported in part by a grant from the Pfizer Medical Education Group.


Eligibility criteria: Inclusion Criteria:

Parent with

1. adolescent aged 11-17 years;
2. adolescent with ≥1 chronic medical condition;
3. adolescent with clinic visit in last 12 months;
4. cell phone number listed in hospital registration system

Exclusion Criteria:

Parent who:

1. does not speak English or Spanish;
2. is unwilling to receive text message vaccine reminders;
3. anticipates moving from area in coming 12 months

Primary outcomes:
measure: Percentage of eligible subjects who received HPV1, influenza, and/or pneumococcal vaccine(s)
timeFrame: 12 weeks after intervention start
Secondary outcomes:
measure: Percentage of eligible subjects who received HPV1, influenza, and/or pneumococcal vaccine(s)
timeFrame: 4 weeks after intervention start
measure: Percentage of eligible subjects who received HPV1, influenza, and/or pneumococcal vaccine(s)
timeFrame: 24 weeks after intervention start
measure: Percentage of eligible subjects with missed opportunities for HPV1, influenza, and/or pneumococcal vaccination
timeFrame: 4 weeks after intervention start
measure: Percentage of eligible subjects with missed opportunities for HPV1, influenza, and/or pneumococcal vaccination
timeFrame: 12 weeks after intervention start
measure: Percentage of eligible subjects with missed opportunities for HPV1, influenza, and/or pneumococcal vaccination
timeFrame: 24 weeks after intervention start
Other outcomes:
Locations:
city: New York
country: United States
facility: NewYork-Presbyterian Hospital/Columbia University Medical Center
state: New York
Study officials:
affiliation: Columbia University
name: Annika M Hofstetter, MD, PhD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hofstetter AM, Barrett A, Camargo S, Rosenthal SL, Stockwell MS. Text message reminders for vaccination of adolescents with chronic medical conditions: A randomized clinical trial. Vaccine. 2017 Aug 16;35(35 Pt B):4554-4560. doi: 10.1016/j.vaccine.2017.07.022. Epub 2017 Jul 21.